MacroGenics (MGNX) Stock Price, News & Analysis

Company Overview

MacroGenics, Inc. is a biopharmaceutical company focused on developing antibody-based therapies for cancer and immune-mediated diseases. Headquartered in Rockville, Maryland, the company uses its proprietary DART platform and other antibody technologies to create treatments designed to modulate immune responses and target disease-associated cells.

MacroGenics’ portfolio includes MARGENZA (margetuximab-cmkb), an antibody therapy approved in the United States for certain patients with HER2-positive metastatic breast cancer. The company also develops investigational therapies that address targets involved in immune regulation, tumor growth and cellular signaling, including bispecific antibodies and antibody-drug conjugates.

Founded in 2000, MacroGenics has advanced programs through internal research and collaborations with pharmaceutical companies. Its products and development activities are directed primarily toward global cancer and immunology markets, with commercialization and development arrangements varying by program and geography. Scott Koenig, M.D., Ph.D., is the company’s founder, president and chief executive officer.

Key Stats

• Today's Range: $2.32 to $2.42
• 50-Day Range: $2.19 to $4.40
• 52-Week Range: $1.32 to $5.08
• Volume: 451,206 shs
• Average Volume: 1.06 million shs
• Market Capitalization: $147.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Hold

MacroGenics Stock Analysis - MarketRank™

MacroGenics scored higher than 57% of companies evaluated by MarketBeat, and ranked 432nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

MacroGenics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

MacroGenics has a consensus price target of $8.50, representing about 266.4% upside from its current price of $2.32.

Amount of Analyst Coverage

MacroGenics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for MacroGenics are expected to decrease in the coming year, from ($1.14) to ($1.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MacroGenics is -10.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of MacroGenics is -10.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

MacroGenics has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.99% of the float of MacroGenics has been sold short.

Short Interest Ratio / Days to Cover

MacroGenics has a short interest ratio ("days to cover") of 3.86, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in MacroGenics has recently decreased by 2.19%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MacroGenics does not currently pay a dividend.

Dividend Growth

MacroGenics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.26

News Sentiment

MacroGenics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for MacroGenics this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added MacroGenics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, MacroGenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $129,086.00 in company stock.

Percentage Held by Insiders

13.60% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 11/11/2026
• Next Earnings (Estimated): 11/11/2026
• Stifel 2026 Healthcare Conference 2026: 11/11/2026
• 9th Annual Evercore ISI HealthCONx Conference: 11/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MGNX
• CIK: 1125345
• Web: www.macrogenics.com
• Phone: (301) 251-5172
• Fax: 301-251-5321
• Employees: 293
• Year Founded: 2000

Price Target and Rating

• Average Price Target for MacroGenics: $8.50
• High Price Target: $11.00
• Low Price Target: $6.00
• Potential Upside/Downside: +266.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.62 million
• Net Margins: -8.70%
• Pretax Margin: -58.48%
• Return on Equity: -109.26%
• Return on Assets: -18.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.96
• Quick Ratio: 2.96

Sales & Book Value

• Annual Sales: $149.50 million
• Price / Sales: 0.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.88 per share
• Price / Book: 2.64

Miscellaneous

• Outstanding Shares: 63,700,000
• Free Float: 55,037,000
• Market Cap: $147.78 million
• Optionable: Optionable
• Beta: 1.33